Lescarden Receives Patent for Osteoarthritis Treatment

Lescarden Receives Patent for Osteoarthritis Treatment

NEW YORK--Lescarden Inc. (www.lescarden.com) was awarded a U.S. patent (No. 6,117,851) for its product, Poly-NAG®, as a treatment forosteoarthritis. The patent filing included clinical trials on the bioavailability and product efficacy in patients suffering fromosteoarthritis. Poly-NAG (poly-N-acetyl-D-glucosamine) is derived from shellfish chitin and is a specially processed short chain polymer ofglucosamine.